Radiopharmaceutical developer Cerveau Technologies said it has expanded the production network for its F-18 MK-6240 investigational tau imaging agent for PET scans.
Cerveau has recently qualified F-18 MK-6240 production sites in Hayward, CA; Houston; Phoenix; and Birmingham, AL, and at academic sites at Johns Hopkins University and Columbia University. With the addition of these six locations, the company said there are now 16 production sites in the U.S., Canada, Australia, and Belgium for the agent, which is designed to assess the status and progression of neurofibrillary tangles in the brain on PET studies.
In addition, 20 additional sites in Canada, the U.S., Japan, Australia, Europe, and China are all undergoing capital expansion, technology transfer, and start-up processes, according to the vendor. Collectively, these sites will support a range of research and therapy clinical trial programs around the world, and they will ultimately support imaging biomarkers licensed by Cerveau and its research and development partners, the company said.
